Publications by authors named "Anita Howe"

Claim this Profile
C
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Anita Y M Howe, Chaturaka Rodrigo, Evan B Cunningham, Mark W Douglas, Julia Dietz

JHEP Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
Anita Y M Howe, Francesca Ceccherini-Silberstein, Julia Dietz, Stephanie Popping, Jason Grebely

Viruses· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.
Hope R Lapointe, Weiyan Dong, Winnie W Y Dong, Don Kirkby, Conan Woods, Anita Y M Howe

Viruses· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs.
Vincent Montoya, Anita Y M Howe, Weiyan Y Dong, Winnie Dong, Chanson J Brumme

Sci Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance.
Mark W Douglas, Enoch S E Tay, Dao Sen Wang, Adrian T L Ong, Caroline Wilson, Anita Y Howe

Hepatol Commun· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections.
Andrea D Olmstead, Vincent Montoya, Celia K Chui, Winnie Dong, Jeffrey B Joy, Anita Y M Howe

Infect Genet Evol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
Shuntai Zhou, Sara E Williford, David R McGivern, Christina L Burch, Fengyu Hu, Anita Y M Howe

Antiviral Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39].
Maria C Sorbo, Valeria Cento, Velia C Di Maio, Anita Y M Howe, Federico Garcia

Drug Resist Updat· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.
David Bonsall, Stuart Black, Anita Ym Howe, Robert Chase, Paul Ingravallo

Infect Drug Resist· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
Maria C Sorbo, Valeria Cento, Velia C Di Maio, Anita Y M Howe, Federico Garcia

Drug Resist Updat· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.
Bradley R Jones, Anita Y M Howe, P Richard Harrigan, Jeffrey B Joy

Virus Evol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
Simone Susser, Julia Dietz, Bernhard Schlevogt, Eli Zuckerman, Mira Barak, Anita Howe

J Hepatol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
Ernest Asante-Appiah, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Robert Chase, Anita Howe

Antimicrob Agents Chemother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.
Sofia R Bartlett, Jason Grebely, Auda A Eltahla, Jacqueline D Reeves, Anita Y M Howe

Hepatol Commun· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Ira M Jacobson, Eric Lawitz, Paul Y Kwo, Christophe Hézode, Cheng-Yuan Peng, Anita Y M Howe

Gastroenterology· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Eric Lawitz, Fred Poordad, Julio A Gutierrez, Jennifer T Wells, Carmen E Landaverde, Anita Howe

Hepatology· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Gregory J Dore, Frederick Altice, Alain H Litwin, Olav Dalgard, Edward J Gane, Anita Y M Howe

Ann Intern Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Hiromitsu Kumada, Satoshi Mochida, Fumitaka Suzuki, Kazuaki Chayama, Yoshiyasu Karino, Anita Y M Howe

J Gastroenterol Hepatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Veronica Miller, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand

Hepatology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.
Steven W Ludmerer, Tomona Hirano, Stuart Black, Anita Y M Howe, Wei Chang

Antiviral Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Frederick C Lahser, Karin Bystol, Stephanie Curry, Patricia McMonagle, Ellen Xia, Anita Y M Howe

Antimicrob Agents Chemother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
Norio Hayashi, Makoto Nakamuta, Tetsuo Takehara, Hiromitsu Kumada, Akiko Takase, Anita Yee Mei Howe

J Gastroenterol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Maria Buti, Stuart C Gordon, Eli Zuckerman, Eric Lawitz, Jose L Calleja, Anita Y M Howe

Clin Infect Dis· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus drug resistance-associated substitutions: State of the art summary.
Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand

Hepatology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
Rong Liu, Stephanie Curry, Patricia McMonagle, Wendy W Yeh, Steven W Ludmerer, Anita Y M Howe

Antimicrob Agents Chemother· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis